Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Stock Surges 13 Percent on Positive Study Results

NEW YORK, March 27 (GenomeWeb News) - Shares in Sequenom were up 13.29 percent, or $.09, at $.75 in mid-afternoon trading today after the company said two proof-of-concept molecular diagnostic studies using its MassArray system have garnered positive results.

According to Sequenom, the studies, which were performed at different CLIA-certified laboratories, tested for cystic fibrosis and Factor V Leiden and "yielded absolute equivalence of analytical results generated by the MassArray Compact system when compared with well established systems in current use."

 

The studies were conducted and evaluated by Siemens Medical Solutions of Siemens; Specialty Laboratories; and Bioscientia Institut fur Medizinische Diagnostik, and were part of the molecular diagnostics benchmarking study that was initiated in late 2004 by Siemens and Sequenom.

 

As part of the proof-of-concept research, Specialty Laboratories and Bioscientia tested approximately 1,500 DNA samples for Factor V Leiden and Specialty tested more than 1,000 DNA samples for CFTR, according to Sequenom.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.